Pardes Biosciences to Present at Cowen Healthcare Conference
Pardes Biosciences, Inc. (NASDAQ: PRDS) announced that CEO Thomas G. Wiggans and Chief Scientific Advisor Uri A. Lopatin will present a company overview at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 a.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pardes Biosciences, Inc. (NASDAQ: PRDS) announced that CEO Thomas G. Wiggans and Chief Scientific Advisor Uri A. Lopatin will present a company overview at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 a.m. PT. This event takes place virtually from March 7-9, 2022. Pardes is developing PBI-0451, a novel oral antiviral for SARS-CoV-2 infections, including COVID-19. A live audio webcast of the presentation will be available on Pardes' website, with an archived replay accessible for 30 days.
Details
News Market Reaction – PRDS
The recorded move for PRDS in the trading session of this news was +0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that Thomas G. Wiggans, Chief Executive Officer, and Uri A. Lopatin, M.D., Chief Scientific & Strategic Advisor, will present a company overview at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9, 2022 at 11:10 a.m. PT / 2:10 p.m. ET. The conference will take place virtually from March 7-9, 2022.
A live audio webcast of the presentation will be available in the Investors section of Pardes’ website at www.pardesbio.com, with an archived replay available for 30 days following the event.
About Pardes Biosciences, Inc.
Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. For more information, please visit www.pardesbio.com.
Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.
Investor Contact:
ir@pardesbio.com
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.